To evaluate the anatomical and functional results after ocriplasmin (JETREA, ThromboGenics NV, Iselin, NJ, USA) injection in patients with vitreomacular traction (VMT) with or without macular hole (MH).


Fifteen prospective patients with VMT were treated with a single ocriplasmin injection and followed-up at baseline, 1 week, 1, 3 and 6 months. ETDRS best-corrected visual acuity (BCVA), intraocular pressure and spectral-domain optical coherence tomography (Spectralis, Heidelberg Engineering, Heidelberg, Germany) were performed. Central retinal thickness (CRT), extension and area of the VMT and MH size were also analysed. Ocular and systemic adverse events were collected too.


15 eyes (15 patients) were treated. Mean age was 70.7±6.1 years (64.4% of the patients were women and 78.5% were phakic). Overall, VMT release rate was 64.5%. Four patients presented with MH associated to the VMT. Mean MH size was 305 µm. MH closure rate was 75%. Mean VMT extension was 497.35 µm, mean CRT was 335.64 µm and mean VMT area was 0.41mm2. Baseline BCVA was 68.4 ETDRS letters. At 6 months, mean BCVA improved to 79.2 ETDRS letters. None of the patients suffered any serious ocular or systemic adverse event. Most frequent ocular adverse events were: transient loss of vision, vitreous floaters, photopsia, alteration of vision color, subretinal fluid and outer segment ellipsoid zone loss on SD-OCT, which were mainly transient.


In clinical practice, intravitreal injection of ocriplasmin resolved VMT in 64.5% and closed MH in 75% of the cases. Overall, ocriplasmin is an effective and safe treatment for VMT with or without MH.

Contact Details:

Email: ffaus.salud@gmail.com
Cell Phone: +34653373174

Fernando Faus